Hepanovaincis A Clinical Stage Global Pharmaceutical Company Developing First In Class Drug Candidates For Chronic Liver Diseasesthe Company Was Founded In 2014 In California And Runs Two State Of The Art R&D Centers Located In Gaithersburgmaryland And Shanghai Zhangjiang Hi Tech Parkchinathe Mission Of Hepanova Is To Discoverdevelop And Commercialize Innovative Therapeutics For Chronic Liver Diseases With High Unmet Medical Needshepanova S Compelling Pipelines Include Multiple R&D Programs Targeting At Mashmetabolic Dysfunction Associated Steatohepatitisformerly Known As Nash Liver Fibrosisand Hcchepatocellular Carcinoma The First In Class Mash & Liver Fibrosis Drughpn 01 Is Currently In U Sphase I Clinical Trialshowing Promising Early Resultsit Is Also The Only Mash Candidate Targeting All Major Mechanisms Aehepatic Steatosisinflammationand Fibrosis Simultaneouslywith Strong Efficacy Data In All Three Conditions
